A has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This is the expense the company spent on research and development. Agilent Technologies Inc's research and development for the three months ended in Jan. 2016 was $78 Mil. Its research and development for the trailing twelve months (TTM) ended in Jan. 2016 was $320 Mil.
This is the expense the company spent on research and development.
Agilent Technologies Inc Research & Development for the trailing twelve months (TTM) ended in Jan. 2016 was 81 (Apr. 2015 ) + 79 (Jul. 2015 ) + 82 (Oct. 2015 ) + 78 (Jan. 2016 ) = $320 Mil.
If competitive advantage is created by a patent or tech advantage, at some point it will disappear.
High R&D usually dictates high SG&A which threatens the competitive advantage.
Agilent Technologies Inc Annual Data
|Research & Development||655||685||704||642||612||649||668||337||358||330|
Agilent Technologies Inc Quarterly Data
|Research & Development||-194||88||87||86||97||88||81||79||82||78|
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.